stroke |
16 |
ischemic stroke |
15 |
intracerebral hemorrhage |
14 |
hypertension |
13 |
blood pressure |
11 |
myocardial infarction |
11 |
endothelial function |
9 |
garlic |
9 |
blood pressure variability |
8 |
cardiovascular and cerebrovascular diseases |
8 |
mortality |
8 |
prognosis |
8 |
type 2 diabetes mellitus |
8 |
vascular markers |
8 |
vascular markers of atherosclerosis |
8 |
als |
7 |
antiplatelet medication |
7 |
cutoff |
7 |
genetics |
7 |
hematoma location |
7 |
lacunar infarct |
7 |
next generation sequencing |
7 |
stroke outcome |
7 |
survival |
7 |
cardiovascular event |
6 |
cerebrovascular event |
6 |
ich volume |
6 |
intraventricular extension |
6 |
neurological deterioration |
6 |
spondyloarthritis |
6 |
visit-to-visit blood pressure variability |
6 |
warfarin |
6 |
warfarin-associated ich |
6 |
cerebral microbleed |
5 |
cerebral small vessel disease |
5 |
chronic kidney disease |
5 |
follow-up |
5 |
intracranial hemorrhage |
5 |
magnetic |
5 |
renal impairment |
5 |
resonance imaging |
5 |
secondary prevention |
5 |
survivors |
5 |
acquired myasthenia gravis |
4 |
aquaporin-4 autoantibodies |
4 |
autoimmune |
4 |
azathioprine |
4 |
classical multiple sclerosis |
4 |
clinical outcome |
4 |
coronavirus disease |
4 |
immunosuppressant therapy |
4 |
inflammatory demyelinating disorders |
4 |
low‐density lipoprotein cholesterol |
4 |
neuromyelitis optica spectrum disorders |
4 |
prospective cohort study |
4 |
public health |
4 |
cera |
3 |
esa |
3 |
fatigue |
3 |
hospitalization |
3 |
neurodegenerative diseases |
3 |
pleiotropy |
3 |
renal anemia |
3 |
renal palliative care |
3 |
disease-modification |
2 |
monoamine oxidase-b inhibitors |
2 |
neuroprotection |
2 |
parkinson's disease |
2 |
rasagiline |
2 |
selegiline |
2 |
endovascular thrombectomy |
1 |
geriatric |
1 |